ANKRD36BP2: A Potential Drug Target and Biomarker (G645784)

Target Name: ANKRD36BP2

NCBI ID: G645784

ANKRD36BP2

Other Name(s): Ankyrin repeat domain 36B pseudogene 2 | ankyrin repeat domain 36B pseudogene 2

ANKRD36BP2: A Potential Drug Target and Biomarker

Ankyrin repeat domains (ANKRDs) are a type of gene repeat that are found in various organisms, including humans. These domains are characterized by a repeated sequence of amino acids, which are typically held by a specific RNA-binding protein called ANKRD. The discovery of ANKRDs has led to a new understanding of gene regulation and has the potential to reveal new targets for drugs. One of these targets is ANKRD36BP2, a pseudogene that has been identified in the human genome. In this article, we will explore the potential drug target and biomarker properties of ANKRD36BP2.

Potential Drug Target

The ANKRD36BP2 gene is located on chromosome 16 and encodes a protein that is characterized by a single ANKRD domain. This domain is known for its ability to form a RNA-binding complex with various transcription factors, including RNA factors that play important roles in cell growth, development, and metabolism.

The ANKRD domain is also known for its ability to form a stable interaction with the protein p16INK4a, which is a negative regulator of the Ink4a gene. This interaction between the ANKRD domain and p16INK4a has been shown to play a role in the regulation of cell growth, apoptosis, and other cellular processes.

Given the involvement of ANKRD in various cellular processes, it is a potential drug target. The use of small molecules or antibodies to target the ANKRD36BP2 protein has the potential to modulate cellular processes and lead to therapeutic benefits.

Biomarker

The ANKRD36BP2 gene has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and mental disorders. This is because the ANKRD36BP2 protein is expressed in various tissues and cells and can be used as a protein biomarker for these conditions.

For example, the ANKRD36BP2 protein has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that it may be a useful biomarker for the diagnosis and treatment of these cancers. Additionally, the ANKRD36BP2 protein has been shown to be involved in the regulation of neurotransmitter release and has been implicated in the development and progression of neurodegenerative diseases.

Expression of ANKRD36BP2 in neurodegenerative diseases has also been shown to be associated with the presence of neurofibrillary tangles and the beta-amyloid protein, which are thought to contribute to the development of these conditions. This suggests that ANKRD36BP2 may be a useful biomarker for the diagnosis and treatment of neurodegenerative diseases.

Conclusion

In conclusion, ANKRD36BP2 is a pseudogene that has been identified in the human genome and is characterized by a single ANKRD domain. The ANKRD domain is known for its ability to form a RNA-binding complex with various transcription factors and has been shown to play a role in the regulation of cell growth, apoptosis, and other cellular processes.

The ANKRD36BP2 protein has the potential to be a drug target and a biomarker for several diseases, including cancer, neurodegenerative diseases, and mental disorders. Further research is needed to fully understand the role of ANKRD36BP2 in these conditions and to develop effective treatments.

Protein Name: Ankyrin Repeat Domain 36B Pseudogene 2

The "ANKRD36BP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD36BP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets